WO2021015040A1 - 育毛剤、およびこれを含む飲食品 - Google Patents
育毛剤、およびこれを含む飲食品 Download PDFInfo
- Publication number
- WO2021015040A1 WO2021015040A1 PCT/JP2020/027260 JP2020027260W WO2021015040A1 WO 2021015040 A1 WO2021015040 A1 WO 2021015040A1 JP 2020027260 W JP2020027260 W JP 2020027260W WO 2021015040 A1 WO2021015040 A1 WO 2021015040A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hyp
- gly
- hair
- pro
- collagen
- Prior art date
Links
- 210000004209 hair Anatomy 0.000 title claims abstract description 106
- 235000013305 food Nutrition 0.000 title claims description 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 131
- 150000001413 amino acids Chemical class 0.000 claims abstract description 66
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims abstract description 33
- -1 Leu-Hyp Chemical compound 0.000 claims abstract description 28
- ONPXCLZMBSJLSP-CSMHCCOUSA-N Pro-Hyp Chemical compound C1[C@H](O)C[C@@H](C(O)=O)N1C(=O)[C@H]1NCCC1 ONPXCLZMBSJLSP-CSMHCCOUSA-N 0.000 claims abstract description 27
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 26
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 claims abstract description 17
- KZNQNBZMBZJQJO-YFKPBYRVSA-N glyclproline Chemical compound NCC(=O)N1CCC[C@H]1C(O)=O KZNQNBZMBZJQJO-YFKPBYRVSA-N 0.000 claims abstract description 16
- 108010077515 glycylproline Proteins 0.000 claims abstract description 16
- KIZQGKLMXKGDIV-BQBZGAKWSA-N Pro-Ala-Gly Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 KIZQGKLMXKGDIV-BQBZGAKWSA-N 0.000 claims abstract description 15
- QEDRTIXTEAXNMY-XVMARJQXSA-N 2-[[(2s,4r)-1-[(2s)-2-aminopropanoyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetic acid Chemical compound C[C@H](N)C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC(O)=O QEDRTIXTEAXNMY-XVMARJQXSA-N 0.000 claims abstract description 14
- 150000003839 salts Chemical class 0.000 claims abstract description 14
- WFDSWNXTPKLLOT-UHNVWZDZSA-N 2-[[(2s,4r)-4-hydroxypyrrolidin-1-ium-2-carbonyl]amino]acetate Chemical compound O[C@H]1CN[C@H](C(=O)NCC(O)=O)C1 WFDSWNXTPKLLOT-UHNVWZDZSA-N 0.000 claims abstract description 12
- HVIBGVJOBJJPFB-OFQRNFBNSA-N Gly-Pro-Hyp Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)C(O)CC1 HVIBGVJOBJJPFB-OFQRNFBNSA-N 0.000 claims abstract description 12
- 108010017349 glycyl-prolyl-hydroxyproline Proteins 0.000 claims abstract description 12
- 108010050297 hydroxyprolyl-glycine Proteins 0.000 claims abstract description 12
- RNKSNIBMTUYWSH-YFKPBYRVSA-N L-prolylglycine Chemical compound [O-]C(=O)CNC(=O)[C@@H]1CCC[NH2+]1 RNKSNIBMTUYWSH-YFKPBYRVSA-N 0.000 claims abstract description 10
- FELJDCNGZFDUNR-WDSKDSINSA-N Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 FELJDCNGZFDUNR-WDSKDSINSA-N 0.000 claims abstract description 10
- RWCOTTLHDJWHRS-YUMQZZPRSA-N Pro-Pro Chemical compound OC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 RWCOTTLHDJWHRS-YUMQZZPRSA-N 0.000 claims abstract description 10
- 108010077112 prolyl-proline Proteins 0.000 claims abstract description 10
- 108010029020 prolylglycine Proteins 0.000 claims abstract description 10
- XQLBWXHVZVBNJM-FXQIFTODSA-N Pro-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 XQLBWXHVZVBNJM-FXQIFTODSA-N 0.000 claims abstract description 9
- WJSNJMXOBDSZDL-WOPDTQHZSA-N L-phenylalanyl-L-hydroxyproline Chemical compound C([C@H](N)C(=O)N1[C@@H](C[C@@H](O)C1)C(O)=O)C1=CC=CC=C1 WJSNJMXOBDSZDL-WOPDTQHZSA-N 0.000 claims abstract description 8
- 102000008186 Collagen Human genes 0.000 claims description 83
- 108010035532 Collagen Proteins 0.000 claims description 83
- 229920001436 collagen Polymers 0.000 claims description 83
- 239000000203 mixture Substances 0.000 claims description 64
- 230000003779 hair growth Effects 0.000 claims description 48
- 230000002500 effect on skin Effects 0.000 claims description 31
- 230000001737 promoting effect Effects 0.000 claims description 31
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 30
- 201000004384 Alopecia Diseases 0.000 claims description 21
- 208000024963 hair loss Diseases 0.000 claims description 21
- 230000003676 hair loss Effects 0.000 claims description 21
- 230000010261 cell growth Effects 0.000 claims description 17
- 230000003405 preventing effect Effects 0.000 claims description 12
- 239000007952 growth promoter Substances 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 description 78
- 229940088598 enzyme Drugs 0.000 description 78
- 108090000790 Enzymes Proteins 0.000 description 77
- 229940024606 amino acid Drugs 0.000 description 61
- 235000001014 amino acid Nutrition 0.000 description 61
- 210000004027 cell Anatomy 0.000 description 59
- 230000000694 effects Effects 0.000 description 39
- 238000000034 method Methods 0.000 description 37
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 22
- 229920000159 gelatin Polymers 0.000 description 21
- 108010010803 Gelatin Proteins 0.000 description 18
- 239000008273 gelatin Substances 0.000 description 18
- 235000019322 gelatine Nutrition 0.000 description 18
- 235000011852 gelatine desserts Nutrition 0.000 description 18
- 102100022749 Aminopeptidase N Human genes 0.000 description 16
- 229960002591 hydroxyproline Drugs 0.000 description 16
- QZDDFQLIQRYMBV-UHFFFAOYSA-N 2-[3-nitro-2-(2-nitrophenyl)-4-oxochromen-8-yl]acetic acid Chemical compound OC(=O)CC1=CC=CC(C(C=2[N+]([O-])=O)=O)=C1OC=2C1=CC=CC=C1[N+]([O-])=O QZDDFQLIQRYMBV-UHFFFAOYSA-N 0.000 description 15
- 108010049990 CD13 Antigens Proteins 0.000 description 15
- 239000004471 Glycine Substances 0.000 description 15
- 230000004663 cell proliferation Effects 0.000 description 15
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 14
- 108010016626 Dipeptides Proteins 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 229960002429 proline Drugs 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 125000003277 amino group Chemical group 0.000 description 10
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 9
- 239000002243 precursor Substances 0.000 description 9
- 102000035195 Peptidases Human genes 0.000 description 8
- 108091005804 Peptidases Proteins 0.000 description 8
- 239000004365 Protease Substances 0.000 description 8
- 238000007385 chemical modification Methods 0.000 description 8
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 235000010724 Wisteria floribunda Nutrition 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 210000003128 head Anatomy 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000001542 size-exclusion chromatography Methods 0.000 description 6
- 239000007790 solid phase Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 210000004899 c-terminal region Anatomy 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 235000019419 proteases Nutrition 0.000 description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- 208000008167 Magnesium Deficiency Diseases 0.000 description 4
- 229960003767 alanine Drugs 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 230000003301 hydrolyzing effect Effects 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- 235000004764 magnesium deficiency Nutrition 0.000 description 4
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 4
- 238000004445 quantitative analysis Methods 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 4
- 239000011800 void material Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000007640 basal medium Substances 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 238000005342 ion exchange Methods 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- 238000010647 peptide synthesis reaction Methods 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 230000001766 physiological effect Effects 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 238000010532 solid phase synthesis reaction Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108010022999 Serine Proteases Proteins 0.000 description 2
- 102000012479 Serine Proteases Human genes 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 101710097834 Thiol protease Proteins 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 230000009435 amidation Effects 0.000 description 2
- 238000007112 amidation reaction Methods 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009697 arginine Nutrition 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 229940074360 caffeic acid Drugs 0.000 description 2
- 235000004883 caffeic acid Nutrition 0.000 description 2
- 230000003848 cartilage regeneration Effects 0.000 description 2
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 2
- 230000009849 deactivation Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Chemical compound NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000003741 hair volume Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- KSUIAQLWKGDNGR-BZLSRIERSA-N (2S)-2-amino-3-phenylpropanoic acid (2S,4R)-4-hydroxypyrrolidine-2-carboxylic acid Chemical compound O[C@H]1CN[C@H](C(O)=O)C1.OC(=O)[C@@H](N)CC1=CC=CC=C1 KSUIAQLWKGDNGR-BZLSRIERSA-N 0.000 description 1
- FJPHHBGPPJXISY-KBPBESRZSA-N (2s)-2-[[(2s)-2-[[2-[(2-aminoacetyl)amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CNC(=O)CN)CC1=CC=C(O)C=C1 FJPHHBGPPJXISY-KBPBESRZSA-N 0.000 description 1
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical compound O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 1
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- DDRAYWXTTWQAEA-HJXLNUONSA-N 2-aminoacetic acid;(2s,4r)-4-hydroxypyrrolidine-2-carboxylic acid Chemical compound NCC(O)=O.O[C@H]1CN[C@H](C(O)=O)C1 DDRAYWXTTWQAEA-HJXLNUONSA-N 0.000 description 1
- UVJWCNFWEYPYSP-SNKMQCGQSA-N 2-aminoacetic acid;(2s,4r)-4-hydroxypyrrolidine-2-carboxylic acid;(2s)-pyrrolidine-2-carboxylic acid Chemical compound NCC(O)=O.OC(=O)[C@@H]1CCCN1.O[C@H]1CN[C@H](C(O)=O)C1 UVJWCNFWEYPYSP-SNKMQCGQSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- CXISPYVYMQWFLE-VKHMYHEASA-N Ala-Gly Chemical compound C[C@H]([NH3+])C(=O)NCC([O-])=O CXISPYVYMQWFLE-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108090000915 Aminopeptidases Proteins 0.000 description 1
- 102000004400 Aminopeptidases Human genes 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 108091005658 Basic proteases Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108010004032 Bromelains Proteins 0.000 description 1
- 101710155556 Calcium-dependent protease Proteins 0.000 description 1
- 108090000258 Cathepsin D Proteins 0.000 description 1
- 102000003908 Cathepsin D Human genes 0.000 description 1
- 102000005600 Cathepsins Human genes 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- 108090001069 Chymopapain Proteins 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- AAWZDTNXLSGCEK-UHFFFAOYSA-N Cordycepinsaeure Natural products OC1CC(O)(C(O)=O)CC(O)C1O AAWZDTNXLSGCEK-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000004860 Dipeptidases Human genes 0.000 description 1
- 108090001081 Dipeptidases Proteins 0.000 description 1
- 244000133098 Echinacea angustifolia Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 108090000270 Ficain Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 101001095266 Homo sapiens Prolyl endopeptidase Proteins 0.000 description 1
- 206010021033 Hypomenorrhoea Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 229930182821 L-proline Natural products 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241001638289 Polygala japonica Species 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000056251 Prolyl Oligopeptidases Human genes 0.000 description 1
- AAWZDTNXLSGCEK-ZHQZDSKASA-N Quinic acid Natural products O[C@H]1CC(O)(C(O)=O)C[C@H](O)C1O AAWZDTNXLSGCEK-ZHQZDSKASA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000271567 Struthioniformes Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- ISWQCIVKKSOKNN-UHFFFAOYSA-L Tiron Chemical compound [Na+].[Na+].OC1=CC(S([O-])(=O)=O)=CC(S([O-])(=O)=O)=C1O ISWQCIVKKSOKNN-UHFFFAOYSA-L 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 108010047495 alanylglycine Proteins 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000019835 bromelain Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 229960002976 chymopapain Drugs 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000035614 depigmentation Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000004807 desolvation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000014134 echinacea Nutrition 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 235000019836 ficin Nutrition 0.000 description 1
- POTUGHMKJGOKRI-UHFFFAOYSA-N ficin Chemical compound FI=CI=N POTUGHMKJGOKRI-UHFFFAOYSA-N 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 1
- 108010065713 glycyl-glycyl-tyrosyl-arginine Proteins 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000000752 ionisation method Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229940109850 royal jelly Drugs 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
Definitions
- the present invention relates to a hair restorer and foods and drinks containing the same.
- Collagen hydrolyzate (hereinafter, also referred to as "collagen peptide mixture”) is known to exhibit various physiological activities on living organisms.
- Patent Document 1 discloses that collagen peptide mixture is used as a therapeutic or prophylactic agent for diabetes because it acts on an enzyme that controls insulin secretion.
- Patent Document 2 discloses that the collagen peptide mixture is used as an articular cartilage regeneration promoter because the collagen peptide mixture has an action of promoting cartilage regeneration.
- Japanese Unexamined Patent Publication No. 2005-209488 Patent Document 3 discloses that a collagen peptide mixture is used as a blood pressure lowering agent because the collagen peptide mixture exhibits a blood pressure lowering effect.
- Patent Document 4 Japanese Patent Application Laid-Open No. 2009-161509 (Patent Document 4) and Non-Patent Document 1 disclose that XVII type collagen has a hair loss inhibitory effect and a hair depigmentation inhibitory effect. It has not been known so far that the peptide mixture has an action of promoting hair growth or hair growth in hair or an action of preventing the progression of hair loss. For this reason, research has been enthusiastically pursued as a new physiological activity of the collagen peptide mixture and the collagen-derived amino acids and peptides contained therein to promote hair growth or hair growth in hair or prevent the progression of hair loss. ing.
- the present invention provides a hair restorer containing amino acids, peptides, etc., which promotes hair growth or hair growth in hair, or prevents the progression of hair loss, and foods and drinks containing the same. With the goal.
- the present inventors While searching for a new physiological activity of the collagen peptide mixture, the present inventors have a predetermined amino acid contained in the collagen peptide mixture, a predetermined peptide, and the like to promote hair growth or hair growth in the hair, or to remove hair. It was found that it exerts at least one of the action of preventing the progression of collagen, and the present invention was reached. Specifically, the present invention is as follows.
- the hair restorer according to the present invention includes Hyp, Pro-Hyp, Hyp-Gly, Gly-Pro, Leu-Hyp, Phe-Hyp, Pro-Ala, Pro-Gly, Pro-Pro, Glu-Hyp, Gly-Pro- One or more amino acids or peptides selected from the group consisting of Hyp, Ala-Hyp-Gly, Glu-Hyp-Gly, Pro-Ala-Gly and Ser-Hyp-Gly, or salts thereof, or chemically modified products thereof. contains.
- the amino acids and peptides are preferably derived from collagen.
- the hair restorer is preferably a collagen peptide mixture containing at least one of the amino acids or the peptides.
- the weight average molecular weight of the collagen peptide mixture is preferably 100 Da or more and 8000 Da or less.
- the hair restorer is preferably a cell growth promoter for dermal papilla cells.
- the hair restorer is preferably an agent for promoting hair growth or hair growth on the hair, or an agent for preventing the progression of hair loss.
- the food and drink according to the present invention contains the above-mentioned hair restorer.
- a hair restorer containing amino acids, peptides, etc., which promotes hair growth or hair growth in hair or prevents the progression of hair loss, and foods and drinks containing the same.
- FIG. 5 is a drawing-substituting photograph showing the heads of 11-week-old hairless mice of the first group fed with a magnesium-deficient special diet containing Pro-Hyp.
- the notation in the form of "A to B” means the upper and lower limits of the range (that is, A or more and B or less), and there is no description of the unit in A, and the unit is described only in B. In the case, the unit of A and the unit of B are the same.
- the term "hair growth” in “hair growth agent” means not only “hair growth” which means the action of growing hair, but also “hair growth” which means the action of growing new hair and promoting its growth.
- prevention of progression of hair loss which expresses the action of making it difficult for hair to come off, shall be included.
- the hair restorer according to the present invention includes Hyp, Pro-Hyp, Hyp-Gly, Gly-Pro, Leu-Hyp, Phe-Hyp, Pro-Ala, Pro-Gly, Pro-Pro, Glu-Hyp, Gly-Pro- One or more amino acids or peptides selected from the group consisting of Hyp, Ala-Hyp-Gly, Glu-Hyp-Gly, Pro-Ala-Gly and Ser-Hyp-Gly, or salts thereof, or chemically modified products thereof. contains.
- a hair restorer having such characteristics has an action of promoting cell proliferation of dermal papilla cells, and thus can exert at least one of an action of promoting hair growth or hair growth in hair or an action of preventing the progression of hair loss.
- the hair restorers are Hyp, Pro-Hyp, Hyp-Gly, Gly-Pro, Leu-Hyp, Phe-Hyp, Pro-Ala, Pro-Gly, Pro-Pro, Glu-Hyp, Gly-Pro-Hyp. , Ala-Hyp-Gly, Glu-Hyp-Gly, Pro-Ala-Gly and Ser-Hyp-Gly containing one or more amino acids or peptides selected from the group, or salts thereof, or chemically modified products thereof. To do.
- amino acid is represented by an abbreviation of three-letter notation unless otherwise specified. Further, “amino acid” means an L-type amino acid unless otherwise specified.
- peptide means, for example, "Pro-Hyp", a peptide (dipeptide) arranged from the N-terminal side toward the C-terminal side in the order of proline and hydroxyproline, and "Glu-Hyp-” In the case of “Gly”, it means a peptide (tripeptide) in which glutamate, hydroxyproline, and glycine are arranged in this order from the N-terminal side toward the C-terminal side. This also applies to the description of dipeptides and tripeptides other than "Pro-Hyp" and "Glu-Hyp-Gly”.
- Hair restorers include Hyp, Pro-Hyp, Hyp-Gly, Gly-Pro, Pro-Ala, Pro-Gly, Pro-Pro, Gly-Pro-Hyp, Ala-Hyp-Gly, Glu-Hyp-Gly and Pro- It preferably contains one or more amino acids or peptides selected from the group consisting of Ala-Gly, salts thereof, or chemically modified products thereof. It is more preferable that the hair restorer contains at least one peptide of Pro-Hyp or Hyp-Gly, a salt thereof, or a chemically modified product thereof. Further, the hair restorer may be in a mode containing a combination of Hyp and Pro, or a mode containing a combination of Hyp and Gly. In these cases, the hair restorer can more prominently exhibit the cell growth promoting action of the dermal papilla cells.
- the "salt" of the amino acid or peptide is, for example, an inorganic acid salt such as a hydrochloride, sulfate or phosphate of the amino acid or peptide, a methanesulfonate, a benzenesulfonate, a succinate, a oxalate or the like. It is formed as an inorganic base salt such as an organic acid salt, a sodium salt, a potassium salt and a calcium salt, and an organic base salt such as a triethylammonium salt.
- an inorganic acid salt such as a hydrochloride, sulfate or phosphate of the amino acid or peptide, a methanesulfonate, a benzenesulfonate, a succinate, a oxalate or the like. It is formed as an inorganic base salt such as an organic acid salt, a sodium salt, a potassium salt and a calcium salt, and an organic base salt such as
- the "chemically modified product" of the above amino acid and peptide means a compound in which the free functional group of the amino acid residue as a constituent unit is chemically modified.
- Chemical modification can be carried out, for example, on the hydroxyl group of hydroxyproline, the amino group of the amino acid on the N-terminal (amino-terminal) side, and the carboxyl group of the amino acid on the C-terminal (carboxyl-terminal) side.
- Conventionally known chemical modification techniques for amino acids and peptides are applied to specific means of chemical modification and treatment conditions thereof.
- the chemically modified product of the amino acid and peptide can exhibit an effect of improving solubility from weakly acidic to neutral, and an effect of improving compatibility with other active ingredients.
- a Glu-Hyp-Gly tripeptide can be subjected to O-acetylation or the like as a chemical modification of the hydroxyl group in hydroxyproline.
- This O-acetylation can be carried out, for example, by allowing acetic anhydride to act in an aqueous or non-aqueous solvent.
- esterification, amidation and the like can be performed as a chemical modification of the carboxyl group in glycine.
- the esterification can be carried out by suspending the peptide in methanol and then aerating it with dry hydrogen chloride gas.
- the amidation can be carried out by allowing carbodiimide or the like to act on the peptide.
- methylation can be performed as a chemical modification of the free amino group in the peptide.
- At least one of phosphorylation and sulfation can be performed as a chemical modification of the free hydroxyl group in the peptide.
- the amino acids and peptides are preferably derived from collagen.
- collagen as a raw material has conventionally been used for animal skins, skins, bones, cartilage, tendons, etc. represented by cows, pigs, sheep, chickens, ostriches, etc., or fish bones, skins, scales, etc. It can be obtained by performing known degreasing or decalcification treatment, extraction treatment and the like.
- gelatin can be used as a raw material for the peptide. Gelatin can be obtained by treating the collagen obtained as described above by a conventionally known method such as hot water extraction. Commercially available collagen and gelatin can also be used as raw materials.
- the amino acids and peptides can be obtained by hydrolyzing two or more kinds of endo-type protease and exo-type protease with respect to both or one of the above-mentioned collagen and gelatin.
- the amino acid and peptide are obtained as a collagen peptide mixture mixed with other collagen peptides by the above hydrolysis, and the collagen peptide mixture itself and a partially purified mixture thereof can be used as the hair restorer according to the present invention. it can. That is, the hair restorer is preferably a collagen peptide mixture containing at least one of the above amino acids or the above peptides.
- a purified product containing either the amino acid or the peptide described above can be obtained with high purity.
- the amino acids and peptides are derived from collagen, it is preferable to obtain them by using a method of enzymatically treating collagen or gelatin described later in two steps.
- the weight average molecular weight of the collagen peptide mixture is 100 Da or more and 8000 Da or less.
- the weight average molecular weight of the collagen peptide mixture is more preferably 100 Da or more and 6000 Da or less, and further preferably 100 Da or more and 4000 Da or less.
- the hair restorer exhibits a cell proliferation effect of hair papilla cells more prominently, thereby promoting hair growth and hair growth in the hair and preventing the progression of hair loss. At least one of the actions can be more fully obtained.
- the weight average molecular weight exceeds 8000 Da, the above-mentioned effect of the hair restorer may be insufficient.
- the weight average molecular weight of the collagen peptide mixture can be determined by performing size exclusion chromatography (SEC) under the following measurement conditions.
- a sample containing about 0.2 g of the collagen peptide mixture is added to about 100 ml of distilled water, stirred, and then filtered using a 0.2 ⁇ m filter to measure the weight average molecular weight. (Target object) is prepared. By subjecting this test object to the above-mentioned size exclusion chromatography, the weight average molecular weight of the collagen peptide mixture can be determined.
- the amino acid or peptide contained in the hair restorer can be obtained by a conventionally known method.
- the above amino acid (Hyp) can be obtained by purchasing a commercially available amino acid.
- the amino acids can also be obtained by using a method of hydrolyzing collagen or gelatin.
- the peptides can be obtained by using conventionally known liquid phase or solid phase peptide synthesis methods or methods of hydrolyzing collagen or gelatin, respectively. Can be done. From the viewpoint of efficiency, the peptide is preferably produced by a chemical synthesis method using an amino acid described later, or a method of treating collagen or gelatin described later with an enzyme in two steps.
- the above peptide is a method of treating collagen or gelatin with an enzyme in two steps, a method of omitting a primary enzyme and treating with an enzyme only with a secondary enzyme, and a method of simultaneously performing an enzyme treatment with a primary enzyme and a secondary enzyme. It is also possible to manufacture by using.
- "Glu-Hyp-Gly" will be focused on from the peptides contained in the hair restorer, and a method for producing the same will be described as an example of a method for producing the peptide contained in the hair restorer.
- the above peptide can be obtained by using a general peptide synthesis method.
- a solid phase synthesis method and a liquid phase synthesis method are known.
- the Fmoc method and the Boc method are known as solid-phase synthesis methods.
- the peptide can be obtained by using either the Fmoc method or the Boc method.
- a solid-phase synthesis method of a peptide a method for synthesizing a tripeptide represented by Glu-Hyp-Gly can be carried out as follows.
- beads of polystyrene polymer gel with a diameter of about 0.1 mm whose surface is modified with an amino group are prepared as a solid phase.
- Diisopropylcarbodiimide is separately prepared as a condensing agent.
- the amino group of glycine which is an amino acid on the C-terminal (carboxyl terminal) side, is protected by an Fmoc (fluorenyl-methoxy-carbonyl) group, and the carboxyl of the glycine is subjected to a dehydration reaction using the condensing agent.
- the group and the amino group of the solid phase are peptide-bonded.
- the solid phase is washed with a solvent to remove the residual condensing agent and amino acids, and then the protecting group of the amino group of glycine peptide-bonded to the solid phase is removed (deprotected).
- hydroxyproline whose amino group is protected with an Fmoc group is prepared, and the carboxyl group of this hydroxyproline and the deprotected amino group of glycine are peptide-bonded by using the condensing agent.
- Glu- A tripeptide represented by Hyper-Gly is synthesized.
- the tripeptide can be produced by deprotecting the amino group of the glutamic acid and further immersing the tripeptide from the solid phase with trifluoroacetic acid to cleave it.
- enzyme treatment of collagen or gelatin in two steps means the following. That is, an enzyme having aminopeptidase N activity, an enzyme having both aminopeptidase N activity and prolyltripeptidylaminopeptidase activity, after performing primary enzyme treatment by a conventionally known method for cleaving the peptide bond of collagen or gelatin.
- the secondary enzyme treatment is carried out by a combination of an enzyme having an aminopeptidase N activity and an enzyme having a prolyltripeptidyl aminopeptidase activity.
- the collagen peptide mixture containing the Glu-Hyp-Gly can be obtained from the collagen peptide mixture precursor.
- the method of enzymatically treating collagen or gelatin in two steps will be described in more detail below.
- the enzyme used in the primary enzyme treatment is not particularly limited as long as it is an enzyme capable of cleaving the peptide bond of collagen or gelatin, and any proteolytic enzyme can be used. Specific examples thereof include collagenase, thiol protease, serine protease, acidic protease, alkaline protease, metal protease and the like, and one selected from these groups may be used alone, or two or more thereof may be used in combination. You may. As the thiol protease, plant-derived chymopapain, papain, bromelain, ficin, animal-derived cathepsin, calcium-dependent protease and the like can be used.
- serine protease trypsin, cathepsin D and the like can be used.
- acidic protease pepsin, chymotrypsin and the like can be used.
- an enzyme derived from a pathogenic microorganism should not be used, and another enzyme should be used. Is preferable.
- the amount of enzyme in the primary enzyme treatment for example, it is preferable that the above-mentioned enzyme is 0.1 to 5 parts by mass with respect to 100 parts by mass of collagen or gelatin.
- the treatment temperature in the primary enzyme treatment is preferably 30 to 65 ° C., and the treatment time is preferably 10 minutes to 72 hours.
- the weight average molecular weight of the collagen peptide mixture precursor obtained by the above-mentioned primary enzyme treatment is preferably 500 to 20000 Da, more preferably 500 to 10000 Da, and further preferably 500 to 8000 Da. If the weight average molecular weight is within the above range, it can be said that a peptide having an appropriate molecular weight is sufficiently produced.
- the enzyme can be inactivated as needed.
- the deactivation temperature in this case is preferably, for example, 70 to 100 ° C.
- the weight average molecular weight of the collagen peptide mixture precursor can be determined by the method using SEC described above.
- Examples of the enzyme used in the secondary enzyme treatment include an enzyme having aminopeptidase N activity, an enzyme having both aminopeptidase N activity and prolyltripeptidylaminopeptidase activity, or an enzyme having aminopeptidase N activity and prolyltripeptidylaminopeptidase.
- a combination of active enzymes can be mentioned.
- the "enzyme having aminopeptidase N activity” in the present specification is a peptidase having a function of releasing an amino acid from the N-terminal side of a peptide chain, and is the second non-proline or hydroxyproline from the N-terminal side.
- An enzyme that acts in the presence of amino acids is a peptidase having a function of releasing an amino acid from the N-terminal side of a peptide chain, and is the second non-proline or hydroxyproline from the N-terminal side.
- the term "enzyme having prolyltripeptidylaminopeptidase activity” refers to a peptidase that releases only the N-terminal 3 amino acid residue from a peptide in which the third N-terminal side is proline or hydroxyproline. ..
- the enzyme used in the secondary enzyme treatment when considering the use of the hair restorer according to the present invention in pharmaceuticals, foods for specified health uses, etc., it is possible to use other enzymes without using enzymes derived from pathogenic microorganisms. preferable.
- Examples of the enzyme having aminopeptidase N activity include aminopeptidase N (EC 3.4.11.2 .; T. Yoshimoto et al., Agric. Biol. Chem., 52: 217-225 (1988)). be able to. Further, for example, an enzyme having aminopeptidase N activity derived from the genus Aspergillus can be mentioned. Examples of the enzyme having prolyltripeptidylaminopeptidase activity include prolyltripeptidylaminopeptidase (EC 3.4.14 .; A. Banbula et al., J. Biol. Chem., 274: 9246-9252 (1999)). ) And so on.
- a collagen peptide mixture containing a peptide that was not contained in the collagen peptide mixture precursor can be obtained.
- a collagen peptide mixture containing the above Glu-Hyp-Gly can be obtained.
- the amount of enzyme in the secondary enzyme treatment for example, it is preferable that the above-mentioned enzyme is 0.01 to 5 parts by mass with respect to 100 parts by mass of the collagen peptide mixture precursor.
- the treatment temperature in the secondary enzyme treatment is preferably 30 to 65 ° C., and the treatment time is preferably 10 minutes to 72 hours.
- the weight average molecular weight of the collagen peptide mixture obtained by the above secondary enzyme treatment is preferably 100 to 10000 Da, more preferably 100 to 8000 Da, and further preferably 100 to 4000 Da.
- the weight average molecular weight of the collagen peptide mixture can also be determined by the method using SEC described above.
- the secondary enzyme treatment is carried out mainly for the purpose of producing the above-mentioned Glu-Hyp-Gly tripeptide. Therefore, it is preferable to adjust the amount of enzyme, the treatment temperature, the treatment time and the pH in the secondary enzyme treatment so that the peptide contained in the collagen peptide mixture precursor is not excessively hydrolyzed. Thereby, it is preferable that the collagen peptide mixture is within the range of the above-mentioned weight average molecular weight.
- the enzyme needs to be inactivated.
- the deactivation temperature is preferably, for example, 70 to 100 ° C.
- an enzyme having different activities can be used, and two kinds of enzymes having different activities can be used.
- the above can be used together. This makes it possible to decompose and remove by-products.
- the enzyme used in this case is preferably selected as appropriate according to the type of collagen as a raw material and the type of enzyme used for the primary enzyme treatment. Examples of the different activities described above include dipeptidase activity such as proridase activity and hydroxyproridase activity. As a result, dipeptides and the like, which are by-products, can be decomposed and removed.
- the aminopeptidase N activity is basically an activity that releases amino acids on the N-terminal side one by one. Therefore, when the collagen peptide mixture precursor obtained by the primary enzyme treatment contains a peptide having an extremely large molecular weight, the treatment time is significantly prolonged when the secondary enzyme treatment is performed only with an enzyme having aminopeptidase N activity. To do.
- prolyl oligopeptidase which is an endopeptidase having an activity of hydrolyzing the carboxyl group side of proline (proridase activity)
- prolyl oligopeptidase which is an endopeptidase having an activity of hydrolyzing the carboxyl group side of proline (proridase activity)
- a peptide having a relatively large molecular weight can be produced by the primary enzyme treatment.
- This peptide can have, for example, the amino acid sequence represented by [X 1 -Gly-X 2- Glu-Hyp-Gly] (X 1 and X 2 ⁇ Hyp).
- an enzyme having aminopeptidase N activity acts on the peptide represented by the above [X 1 -Gly-X 2- Glu-Hyp-Gly], and X 1 at the N-terminal is released.
- a peptide having an amino acid sequence represented by [Gly-X 2- Glu-Hyp-Gly] is obtained.
- an enzyme having aminopeptidase N activity acts twice on the peptide represented by the above [Gly-X 2- Glu-Hyp-Gly] to release glycine and X 2 , thereby [Glu-Hyp. -Gly] is obtained.
- a collagen peptide mixture containing Glu-Hyp-Gly By carrying out the above-mentioned two-step enzyme treatment, a collagen peptide mixture containing Glu-Hyp-Gly can be produced. Since the collagen peptide mixture also contains peptides other than the tripeptide represented by Glu-Hyp-Gly, it is preferable to purify it as necessary.
- a conventionally known method can be used, for example, various liquid chromatography such as ultrafiltration, size exclusion chromatography, ion exchange chromatography, reverse phase chromatography, affinity chromatography and the like are used. be able to.
- the collagen peptide mixture can be purified by the following operation. That is, about 2 g / 10 mL of the collagen peptide mixture is loaded on an ion exchange column (for example, trade name: "Toyopearl (registered trademark) DEAE-650", manufactured by Tosoh Corporation), and then the first void volume eluted with distilled water. Collect the fraction. Next, the first void volume fraction is loaded on a column having an ion exchange group opposite to that of the ion exchange column (for example, trade name: "Toyopearl (registered trademark) SP-650", manufactured by Tosoh Corporation), and then distilled. Collect the second void volume fraction eluted with water.
- an ion exchange column for example, trade name: "Toyopearl (registered trademark) DEAE-650", manufactured by Tosoh Corporation
- the first void volume fraction is loaded on a column having an ion exchange group opposite to that of the ion exchange column (for example
- the second void volume fraction was loaded on a gel filtration column (for example, trade name: "Sephadex LH-20", manufactured by GE Healthcare Japan Co., Ltd.) and eluted with a 30 mass% methanol aqueous solution.
- a fraction containing the Glu-Hyp-Gly tripeptide is collected.
- 0.1 mass% trifluoroacetic acid was added to this fraction using high performance liquid chromatography (HPLC) loaded with a reverse phase column (for example, trade name: " ⁇ Bondasphere 5 ⁇ C18 300 ⁇ column", manufactured by Waters).
- HPLC high performance liquid chromatography
- the hair restorer according to the present invention is preferably a cell growth promoter for hair papilla cells.
- the hair restorer is Hyp, Pro-Hyp, Hyp-Gly, Gly-Pro, Leu-Hyp, Ph-Hyp, Pro-Ala, Pro-Gly, Pro-Pro, Glu-Hyp, Gly-Pro- One or more amino acids or peptides selected from the group consisting of Hyp, Ala-Hyp-Gly, Glu-Hyp-Gly, Pro-Ala-Gly and Ser-Hyp-Gly, or salts thereof, or chemically modified products thereof.
- the hair restorer can exert at least one of a hair growth or hair growth promoting action on the hair or a hair loss progression preventing action. Therefore, the hair restorer can be applied as an agent for promoting cell proliferation of dermal papilla cells to promote cell proliferation of dermal papilla cells.
- the hair restorer contains the above amino acids, peptides, salts thereof, or chemically modified substances thereof, it is also preferable that the hair restorer is an agent for promoting hair growth or hair growth in hair, or an agent for preventing the progression of hair loss.
- the hair restorer has a cell proliferation promoting action of hair papilla cells as described above, it is suitable for a treatment that promotes hair growth or hair growth by proliferating hair papilla cells as an agent for promoting hair growth or hair growth in hair. Can be used.
- the hair restorer can also be used for the purpose of suppressing or preventing the progression of hair loss caused by the decrease of hair papilla cells by proliferating the hair papilla cells as a hair loss progression preventive agent in the hair.
- the hair restorer can be administered orally or parenterally in various forms.
- the dosage form can be, for example, tablets, granules, capsules, powders, liquids, suspensions, emulsified preparations and the like.
- the above-mentioned dosage form hair restorer can be mixed with food and drink.
- Hair restorers include, for example, at least one of the amino acids, amino acid combinations, or peptides described above, which are rapidly absorbed in the intestinal tract and can be taken by oral administration.
- the hair restorer When administered parenterally, can be in the form of an external preparation such as an ointment, cream or lotion, or a transdermal preparation. Further, it can be used as a liquid agent or a coating agent for direct application to the scalp.
- the dose of the hair restorer varies depending on the subject's age, gender, body weight, sensitivity difference, administration method, administration interval, type of preparation, etc.
- the dose is preferably 0.0001 to 2500 mg / kg, more preferably 0.0001 to 500 mg / kg, for example, per day for an adult.
- the dosage form is, for example, a tablet
- the hair restorer is a tablet containing 0.001 to 80% by mass of the hair restorer, and when the dosage form is, for example, 0.001 to 100% by mass of the hair restorer. It can be a contained powder.
- the above-mentioned dose can be appropriately determined with reference to the dose in the case of oral administration, such as when it is administered parenterally or when it is administered by a preparation in another form.
- the hair restorer can be administered once to several times a day, or once every one to several days.
- the hair restorer can appropriately contain other active ingredients, carriers for preparations, etc. as long as it does not adversely affect the effects of the present invention.
- active ingredients include inulin, caffeic acid, quinic acid and derivatives thereof, extracts from majorum, gold-free, polygala japonica and various herbal medicines such as white eyebrows, hawk claws, royal jelly, extracts from echinacea. , Extract from caffeic acid, extract from cupuas, etc.
- diluents binders (syrup, gum arabic, gelatin, sorbitol, tragacant, polyvinylpyrrolidone), excipients (lactose, sucrose, corn starch) , Potassium phosphate, sorbitol, glycine), lubricants (magnesium stearate, talc, polyethylene glycol, silica), disintegrants (potassium starch) and wetting agents (sodium lauryl sulfate) and the like.
- the hair restorer according to the present invention includes Hyp, Pro-Hyp, Hyp-Gly, Gly-Pro, Leu-Hyp, Phe-Hyp, Pro-Ala, Pro-Gly, Pro-Pro, Glu-Hyp, One or more amino acids or peptides selected from the group consisting of Gly-Pro-Hyp, Ala-Hyp-Gly, Glu-Hyp-Gly, Pro-Ala-Gly and Ser-Hyp-Gly, or salts thereof, or salts thereof. Contains a chemically modified product.
- the hair restorer has an action of promoting cell proliferation of dermal papilla cells as an unknown attribute of the above-mentioned amino acid or peptide, and thus exerts at least one of an action of promoting hair growth or hair growth in hair or an action of preventing the progression of hair loss.
- the present invention can be said to be the above-mentioned amino acid or peptide for promoting hair growth or hair growth in hair or for preventing the progression of hair loss, or a salt thereof, or a chemically modified product thereof.
- the food and drink according to the present invention contains the above-mentioned hair restorer.
- the above-mentioned peptide which is preferably contained in a hair restorer, is rapidly absorbed in the intestinal tract as described above, and thus can be ingested by oral administration. Therefore, the present invention can be mixed with a meal or a beverage as a food or drink containing the above-mentioned hair restorer. Further, the food or drink according to the present invention can also be used as a food for specified health use or a food with functional claims.
- the concentration of the hair restorer contained in food and drink is preferably 0.001 to 100% by mass.
- Example 1 Cell biological test (in vitro test)]
- Sample preparation ⁇ Preparation of amino acid, peptide and collagen peptide mixture>
- amino acids, amino acid combinations, dipeptides, tripeptides and collagen peptide mixtures shown in Tables 1 and 2 described later are produced by the methods described above, or from manufacturers described below. Prepared by obtaining.
- amino acids amino acid combinations and peptides shown in Table 1, abbreviations for expressing amino acids in one letter are used.
- PO is a dipeptide represented by proline-hydroxyproline (trade name: “G-3025”, manufactured by BACHEEM)
- OG is a dipeptide represented by hydroxyproline-glycine (trade name: “G-3025”, manufactured by BACHEEM).
- GPO is a tripeptide (manufactured by PH Japan Co., Ltd.) represented by glycine-proline-hydroxyproline.
- PO means a peptide arranged from the N-terminal side toward the C-terminal side in the order of proline and hydroxyproline. This also applies to the description of peptides other than "PO”.
- AOG is a tripeptide represented by alanine-hydroxyproline-glycine (manufactured by PH Japan Co., Ltd.)
- EOG is a tripeptide represented by glutamic acid-hydroxyproline-glycine (manufactured by PH Japan Co., Ltd.).
- SOG is a tripeptide represented by serine-hydroxyproline-glycine (manufactured by PH Japan Co., Ltd.)
- GP is a dipeptide represented by glycine-proline (trade name: "G-3015", (Made by BACHEEM).
- LO is a dipeptide represented by leucine-hydroxyproline (manufactured by PH Japan Co., Ltd.)
- FO is a dipeptide represented by phenylalanine-hydroxyproline (manufactured by PH Japan Co., Ltd.)
- EO is a dipeptide represented by glutamic acid-hydroxyproline (manufactured by PH Japan Co., Ltd.).
- PA is a dipeptide represented by proline-alanine (manufactured by PAH Japan Co., Ltd.)
- PAG is a tripeptide represented by proline-alanine-glycine (manufactured by PAH Japan Co., Ltd.).
- PG is a dipeptide represented by proline-glycine (manufactured by PH Japan Co., Ltd.).
- PP is a dipeptide represented by proline-proline (manufactured by PH Japan Co., Ltd.).
- the collagen peptide mixture A (trade name: "TYPE-S", manufactured by Nitta Gelatin Co., Ltd., weight average molecular weight (Mw): about 750 Da) shown in Table 2 was subjected to LC- under the conditions described later.
- MS / MS the following composition was included.
- the collagen peptide mixture B (trade name: "Korapep PU", manufactured by Nitta Gelatin Co., Ltd., weight average molecular weight (Mw): about 630 Da) shown in Table 2 was subjected to LC-MS / MS under the conditions described later. In the quantitative analysis by, the following composition was included. Pro-Hyp: 8ppm, Hyp-Gly: 3447ppm, Gly-Pro-Hyp: 36ppm, Ala-Hyp-Gly: 436ppm, Glu-Hyp-Gly: 4ppm, Ser-Hyp-Gly: 120ppm, Gly-Pro: 2379ppm, Pro-Ala-Gly: 2645 ppm, total: 9074 ppm.
- a basal medium (trade name: “Follicle Dermal Paper Cell Basic Medium”, manufactured by Takara Bio Co., Ltd.) containing a growth factor attached at the time of obtaining the above-mentioned hair papilla cells was supplied to each well, and each well The dermal papilla cells were precultured in wells for 24 hours at 37 ° C.
- the basal medium in each well was used as another basal medium containing no growth factor (trade name: "Follicle Thermal Papilla Cell Basic Medium”). , Made by Takara Bio Co., Ltd.) was replaced with 200 ⁇ L. Based on the above, dermal papilla cells for determining whether or not cell proliferation is promoted by adding the above sample were prepared.
- the number of surviving cells was counted for each dermal papilla cell in the well to which purified water or each sample was added by the neutral red method.
- the neutral red method is a method in which neutral red is added into a well in which cells are cultured so that the final concentration becomes 150 ⁇ g / mL, and after culturing for 20 minutes, PBS (phosphate buffered saline) is used. Then, 200 ⁇ L of a 50 mass% ethanol solution containing 1 mass% acetic acid is added as an extract into the well, and the mixture is stirred. Then, it refers to a method of measuring the number of viable cells in the well by measuring the absorbance of the well containing neutral red at a wavelength of 540 nm.
- the number of viable cells of the dermal papilla cells in the well to which each sample was added was determined as the cell proliferation rate (%) with respect to the number of viable cells of the dermal papilla cells (control specimen) in the well to which purified water was added.
- the cell growth promoting action of dermal papilla cells possessed by each sample was evaluated.
- the significance of the cell growth promoting action of the dermal papilla cells possessed by each sample was evaluated by statistically processing the cell growth rate (%). To evaluate this significance, software (trade name: "Excel Statistics (Ver2.1)", manufactured by Social Information Service Co., Ltd.) was used as statistical processing, and Threshold-Grubbs (two-sided test) was executed, and the significance level was evaluated.
- 0.05 was set as the threshold value as (P value). After that, it was decided to make a judgment by executing Student's t-test (t test). The results are shown in Tables 1 and 2. Among the samples 1 to 2, it was judged that the cell proliferation promoting action of the dermal papilla cells was significant in the samples marked with "++”. In the samples marked with "+”, the cell proliferation rate (%) was determined. It exceeded 100.
- One or more amino acids or peptides selected from the group consisting of Hyp, Ala-Hyp-Gly, Glu-Hyp-Gly, Pro-Ala-Gly and Ser-Hyp-Gly all have a cell growth promoting action on hair papilla cells.
- a collagen peptide mixture containing these amino acids or peptides also had a cell growth promoting effect on dermal papilla cells.
- the combination of Pro and Hyp amino acids and the combination of Hyp and Gly amino acids also had a cell growth promoting effect on dermal papilla cells.
- the above amino acids and peptides, and the collagen peptide mixture containing them are effective as a hair growth agent, specifically, a cell growth promoter for hair papilla cells, a hair growth or hair growth promoter in hair, or a hair loss progression preventive agent. It was suggested that.
- Example 2 Confirmation test of hair growth effect and hair growth effect using hairless mouse (in vivo test)]
- Thirty hairless mice containing a mixture of males and females 8 weeks old were prepared by obtaining them from Hoshino Experimental Animal Co., Ltd.
- the above hairless mice were divided into the following 5 groups of 6 mice without distinguishing between males and females. That is, the above multiple groups are the normal group fed with normal feed (trade name: "Lab MR Stock", manufactured by Nippon Agricultural Industry Co., Ltd.) and the magnesium deficiency special feed (trade name: "HR-AD feed”, manufactured by Nippon Agricultural Products Co., Ltd.).
- the control group given (manufactured by Kogyo Co., Ltd.), the first group fed with a mixed feed in which Pro-Hyp was added to the magnesium deficiency special feed so that its content was 0.3% by mass, and the magnesium deficiency
- the collagen peptide mixture C is a collagen peptide mixture under development by Nitta Gelatin Co., Ltd., and contained the following composition in a quantitative analysis by LC-MS / MS performed under the above conditions.
- FIG. 1 shows the heads of 11-week-old hairless mice in the control group fed a magnesium-deficient special diet.
- FIG. 2 shows the heads of 11-week-old hairless mice in the first group fed a magnesium-deficient special diet containing Pro-Hyp.
- Pro-Hyp, collagen peptide mixture A and collagen peptide mixture C have a cell growth promoting effect on hair papilla cells, and thus, as a hair growth agent, specifically, a cell growth promoting agent for hair papilla cells, It was suggested that it is effective as an agent for promoting hair growth and hair growth in hair and as an agent for preventing the progression of hair loss.
- Example 3 Control test (cell biology test: in vitro test)]
- Sample preparation ⁇ Preparation of amino acid, peptide and collagen peptide mixture>
- Commercially available amino acids alanine (trade name: "L-alanine", manufactured by Kanto Chemical Co., Ltd., catalog number: 01101-30) and arginine (trade name: "" are used as samples for evaluating the cell growth promoting action on hair papilla cells.
- the dermal papilla cells were prepared by the same method as described in the item ⁇ Preparation of dermal papilla cells> in Example 1 described above.
- Table 4 suggests that alanine, arginine, glutami, and proline have a negative cell growth-promoting effect on hair papilla cells, and that only specific amino acids such as Hyp have a cell growth-promoting effect on hair papilla cells. It was.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Birds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
上記育毛剤は、上記アミノ酸または上記ペプチドのいずれかを少なくとも含むコラーゲンペプチド混合物であることが好ましい。
上記育毛剤は、頭髪における発毛または育毛の促進剤、あるいは脱毛進行予防剤であることが好ましい。
本発明に係る育毛剤は、Hyp、Pro-Hyp、Hyp-Gly、Gly-Pro、Leu-Hyp、Phe-Hyp、Pro-Ala、Pro-Gly、Pro-Pro、Glu-Hyp、Gly-Pro-Hyp、Ala-Hyp-Gly、Glu-Hyp-Gly、Pro-Ala-GlyならびにSer-Hyp-Glyからなる群より選ばれる1以上のアミノ酸またはペプチド、もしくはそれらの塩、あるいはそれらの化学修飾体を含有する。このような特徴を備える育毛剤は、毛乳頭細胞の細胞増殖促進作用を有し、もって頭髪における発毛または育毛の促進作用、あるいは脱毛の進行予防作用の少なくともいずれかを奏することができる。
上述のとおり育毛剤は、Hyp、Pro-Hyp、Hyp-Gly、Gly-Pro、Leu-Hyp、Phe-Hyp、Pro-Ala、Pro-Gly、Pro-Pro、Glu-Hyp、Gly-Pro-Hyp、Ala-Hyp-Gly、Glu-Hyp-Gly、Pro-Ala-GlyならびにSer-Hyp-Glyからなる群より選ばれる1以上のアミノ酸またはペプチド、もしくはそれらの塩、あるいはそれらの化学修飾体を含有する。本明細書において「アミノ酸」は、別段の表記がない限り、3文字表記の略号で表される。さらに「アミノ酸」は、別段の表記がない限り、L型アミノ酸を意味する。本明細書において「ペプチド」は、たとえば「Pro-Hyp」であれば、N末端側からプロリン、ヒドロキシプロリンの順にC末端側へ向けて配列したペプチド(ジペプチド)を意味し、「Glu-Hyp-Gly」であれば、N末端側からグルタミン酸、ヒドロキシプロリン、グリシンの順にC末端側へ向けて配列したペプチド(トリペプチド)を意味する。このことは、「Pro-Hyp」および「Glu-Hyp-Gly」以外のジペプチドおよびトリペプチドの記載についても同様である。
機器 :高速液体クロマトグラフィー(HPLC)(東ソー株式会社製)
カラム:TSKgel(登録商標)G2000SWXL
カラム温度:40℃
カラムサイズ:7.8mmI.D.×30cm、5μm
溶離液:45質量%アセトニトリル(0.1質量%トリフルオロ酢酸を含む)
流速 :1.0mL/min
注入量:10μL
検出 :UV214nm
分子量マーカー:以下の5種を使用
Cytochrom C Mw:12000
Aprotinin Mw:6500
Bacitracin Mw:1450
Gly-Gly-Tyr-Arg Mw:451
Gly-Gly-Gly Mw:189。
育毛剤に含まれる上記アミノ酸またはペプチドは、従来公知の方法により得ることができる。たとえば上記アミノ酸(Hyp)は、市販のアミノ酸を購入することにより得ることができる。上記アミノ酸は、コラーゲンまたはゼラチンを加水分解する方法を用いることにより得ることもできる。
上記ペプチドは、一般的なペプチド合成法を用いて得ることができる。このペプチド合成法としては、固相合成法および液相合成法が公知である。固相合成法には、Fmoc法とBoc法とが知られている。上記ペプチドは、Fmoc法およびBoc法のいずれの方法を用いても得ることができる。ペプチドの固相合成法として、Glu-Hyp-Glyで表されるトリペプチドの合成方法は、次のように行うことができる。
さらにコラーゲンまたはゼラチンを2段階で酵素処理することにより、Glu-Hyp-Glyで表されるトリペプチドを製造する方法は、次のように行うことができる。
1次酵素処理で用いる酵素としては、コラーゲンまたはゼラチンのペプチド結合を切断することが可能な酵素であれば、特に限定されるべきではなく、任意のタンパク質分解酵素を用いることができる。具体的には、コラゲナーゼ、チオールプロテアーゼ、セリンプロテアーゼ、酸性プロテアーゼ、アルカリ性プロテアーゼ、メタルプロテアーゼなどを挙げることができ、これらの群から選ばれる1種を単独で用いてもよく、2種以上を併用してもよい。上記チオールプロテアーゼとしては、植物由来のキモパパイン、パパイン、ブロメライン、フィシン、動物由来のカテプシン、カルシウム依存性プロテアーゼなどを用いることができる。セリンプロテアーゼとしては、トリプシン、カテプシンDなどを用いることができる。酸性プロテアーゼとしては、ペプシン、キモトリプシンなどを用いることができる。1次酵素処理で用いる酵素としては、本発明に係る育毛剤を医薬、特定保健用食品などに用いることを考慮した場合、病原性微生物由来の酵素を用いることなく、それ以外の酵素を用いることが好ましい。
2次酵素処理で用いる酵素としては、アミノペプチダーゼN活性を有する酵素、アミノペプチダーゼN活性およびプロリルトリペプチジルアミノペプチダーゼ活性を併有する酵素、またはアミノペプチダーゼN活性を有する酵素およびプロリルトリペプチジルアミノペプチダーゼ活性を有する酵素の組合せを挙げることができる。ここで本明細書において「アミノペプチダーゼN活性を有する酵素」とは、ペプチド鎖のN末側からアミノ酸を遊離させる働きを有するペプチダーゼであって、N末側から2番目にプロリンあるいはヒドロキシプロリン以外のアミノ酸が存在する場合に作用する酵素をいう。本明細書において「プロリルトリペプチジルアミノペプチダーゼ活性を有する酵素」とは、N末側から3番目がプロリンあるいはヒドロキシプロリンであるペプチドから、N末側の3アミノ酸残基のみを遊離するペプチダーゼをいう。2次酵素処理で用いる酵素も、本発明に係る育毛剤を医薬、特定保健用食品などに用いることを考慮した場合、病原性微生物由来の酵素を用いることなく、それ以外の酵素を用いることが好ましい。
上述した2段階での酵素処理を実行することにより、Glu-Hyp-Glyを含むコラーゲンペプチド混合物を製造することができる。上記コラーゲンペプチド混合物には、Glu-Hyp-Glyで表されるトリペプチド以外のペプチドも含まれているため、必要に応じて精製することが好ましい。この場合の精製方法としては、従来公知の方法を用いることができ、たとえば限外濾過、サイズ排除クロマトグラフィー、イオン交換クロマトグラフィー、逆相クロマトグラフィー、アフィニティクロマトグラフィーなどの各種液体クロマトグラフィーなどを用いることができる。
本発明に係る育毛剤は、毛乳頭細胞の細胞増殖促進剤であることが好ましい。育毛剤は、上述のようにHyp、Pro-Hyp、Hyp-Gly、Gly-Pro、Leu-Hyp、Phe-Hyp、Pro-Ala、Pro-Gly、Pro-Pro、Glu-Hyp、Gly-Pro-Hyp、Ala-Hyp-Gly、Glu-Hyp-Gly、Pro-Ala-GlyならびにSer-Hyp-Glyからなる群より選ばれる1以上のアミノ酸、またはペプチド、もしくはそれらの塩、あるいはそれらの化学修飾体を含有し、もって毛乳頭細胞の細胞増殖促進作用を示すことができる。これにより育毛剤は、頭髪における発毛または育毛の促進作用、あるいは脱毛進行予防作用の少なくともいずれかを奏することができる。したがって育毛剤は、毛乳頭細胞の細胞増殖促進剤として毛乳頭細胞の細胞増殖を促進させる用途に適用することができる。
本発明に係る育毛剤は、上述のようにHyp、Pro-Hyp、Hyp-Gly、Gly-Pro、Leu-Hyp、Phe-Hyp、Pro-Ala、Pro-Gly、Pro-Pro、Glu-Hyp、Gly-Pro-Hyp、Ala-Hyp-Gly、Glu-Hyp-Gly、Pro-Ala-GlyならびにSer-Hyp-Glyからなる群より選ばれる1以上のアミノ酸またはペプチド、もしくはそれらの塩、あるいはそれらの化学修飾体を含有する。育毛剤は、上述したアミノ酸、またはペプチドの未知の属性として毛乳頭細胞の細胞増殖促進作用を有し、もって頭髪における発毛または育毛の促進作用、あるいは脱毛進行予防作用の少なくともいずれかを奏することができる。換言すれば本発明は、頭髪における発毛または育毛の促進用、あるいは脱毛進行予防用の上記アミノ酸またはペプチド、またはその塩、もしくはその化学修飾体であるといえる。
本発明に係る飲食品は、上記育毛剤を含む。たとえば育毛剤に含まれることが好ましい上記のペプチドは、上述のとおり腸管で迅速に吸収されるため、経口投与による摂取が可能である。したがって、本発明は、上記育毛剤を含む飲食品として食事または飲料に混ぜて摂取することができる。さらに本発明に係る飲食品は、特定保健用食品、または機能性表示食品として用いることもできる。飲食品に含まれる育毛剤の濃度としては、0.001~100質量%であることが好ましい。
〔試料の準備〕
<アミノ酸、ペプチドおよびコラーゲンペプチド混合物の準備>
毛乳頭細胞に対する細胞増殖促進作用を評価する試料として、後述する表1~2に表すアミノ酸、アミノ酸の組合せ、ジペプチド、トリペプチドおよびコラーゲンペプチド混合物を、上述した方法により製造し、または後述するメーカーから入手することにより準備した。
Pro-Hyp:8ppm、Hyp-Gly:7389ppm、Gly-Pro-Hyp:8ppm、Ala-Hyp-Gly:199ppm、Glu-Hyp-Gly:9ppm、Ser-Hyp-Gly:176ppm、Gly-Pro:1159ppm、Pro-Ala-Gly:2229ppm、合計:11177ppm。
Pro-Hyp:8ppm、Hyp-Gly:3447ppm、Gly-Pro-Hyp:36ppm、Ala-Hyp-Gly:436ppm、Glu-Hyp-Gly:4ppm、Ser-Hyp-Gly:120ppm、Gly-Pro:2379ppm、Pro-Ala-Gly:2645ppm、合計:9074ppm。
HPLC装置:「ACQUITY UPLC H-Class Bio」、Waters
Corporation製)
カラム:「Hypersil GOLD PFP 2.1×150mm、5μm(Thermo Fisher Scientific. Inc製)
カラム温度:40℃(リニアグラジエント)
移動相:(A)0.2%ギ酸および2mM酢酸アンモニウム含有水溶液
(B)100%メタノール
(グラジエント設定)
Time(分) 流速(μL/分) 移動相(A)の質量%
イニシャル 200 98
3.50 200 98
3.51 400 5
7.00 400 5
7.10 200 98
17.00 200 98
注入量:0.5μl。
イオン化法:Positive ESI
Capilary (kV):1
Desolvation temperature(℃):500
Source temperature(℃):150
MRM条件:
ペプチド(略号) precursor ion(m/z) product ion(m/z)
Gly-Pro(GP) 173 116
Hyp-Gly(OG) 189 86
Pro-Hyp(PO) 229 132
Ala-Hyp-Gly(AOG) 260 189
Glu-Hyp-Gly(EOG) 318 225
Gly-Pro-Hyp(GPO) 286 155
Ser-Hyp-Gly(SOG) 276 189
Pro-Ala-Gly(PAG) 244 141。
まず、ヒト正常毛乳頭細胞HFDPC-C(タカラバイオ株式会社製)を入手し、次いで上記毛乳頭細胞を細胞培養用96ウェルプレート(Corning社製)の各ウェルに0.2×104個/dishとなるように播種した。さらに上記毛乳頭細胞の入手時に付属していた成長因子を含む基本培地(商品名:「Follicle Dermal Papilla Cell Basal Medium」、タカラバイオ株式会社製)を、各ウェルに対し200μLずつ供給するとともに、各ウェル中で上記毛乳頭細胞を24時間、37℃で前培養した。
上述のように準備された毛乳頭細胞に対し、上記の各試料であるアミノ酸、アミノ酸の組合せ、ペプチドおよびコラーゲンペプチド混合物を表1~2に示す最終濃度となるように添加するとともに、各ウェル中で上記毛乳頭細胞を72時間、37℃で培養した。ここで上述のように準備された毛乳頭細胞を含むウェルの一つに対し、精製水を20μL添加し、他の毛乳頭細胞と同様に72時間、37℃で培養することにより対照試験体(コントロール)を準備した。その後、精製水または各試料を添加したウェル中の毛乳頭細胞に対し、それぞれニュートラルレッド法により生存している細胞数(生細胞数)をカウントした。ここで「ニュートラルレッド法」とは、細胞が培養されているウェル中へ最終濃度が150μg/mLとなるようにニュートラルレッドを添加し、20分培養した後、PBS(リン酸緩衝生理食塩水)で洗浄し、さらに上記ウェル中へ抽出液として1質量%酢酸を含む50質量%エタノール溶液200μL添加し、撹拌する。その後、ニュートラルレッドを含む上記ウェルの波長540nmにおける吸光度を測定することにより、上記ウェル中の生細胞数を測定する方法をいう。
表1~2によれば、Hyp、Pro-Hyp、Hyp-Gly、Gly-Pro、Leu-Hyp、Phe-Hyp、Pro-Ala、Pro-Gly、Pro-Pro、Glu-Hyp、Gly-Pro-Hyp、Ala-Hyp-Gly、Glu-Hyp-Gly、Pro-Ala-GlyならびにSer-Hyp-Glyからなる群より選ばれる1以上のアミノ酸、またはペプチドは、いずれも毛乳頭細胞の細胞増殖促進作用を有することが分かった。これらのアミノ酸、またはペプチドを含むコラーゲンペプチド混合物も、毛乳頭細胞の細胞増殖促進作用を有していた。さらにProおよびHypのアミノ酸の組合せ、HypおよびGlyのアミノ酸の組合せも、毛乳頭細胞の細胞増殖促進作用を有していた。これにより上記アミノ酸およびペプチド、ならびにこれらを含むコラーゲンペプチド混合物は、育毛剤として、具体的には毛乳頭細胞の細胞増殖促進剤、頭髪における発毛または育毛の促進剤、あるいは脱毛進行予防剤として有効であることが示唆された。
生後8週齢の雌雄が混在したヘアレスマウス30匹を、星野実験動物株式会社から入手することにより準備した。上記ヘアレスマウスについて、雌雄を区別することなく6匹ずつ次の5群に分けた。すなわち上記の複数群は、通常飼料(商品名:「ラボMRストック」、日本農産工業株式会社製)を与えたノーマル群と、マグネシウム欠乏特殊飼料(商品名:「HR-AD飼料」、日本農産工業株式会社製)を与えたコントール群と、上記マグネシウム欠乏特殊飼料にPro-Hypを、その含有量が0.3質量%となるように加えた混餌を与えた第1群と、上記マグネシウム欠乏特殊飼料に上記コラーゲンペプチド混合物Aを、その含有量が5質量%となるように加えた混餌を与えた第2群と、上記マグネシウム欠乏特殊飼料に後述する組成からなるコラーゲンペプチド混合物Cを、その含有量が2.5質量%となるように加えた混餌を与えた第3群とからなる。
Pro-Hyp:12772ppm、Hyp-Gly:6353ppm、Gly-Pro-Hyp:32010ppm、Ala-Hyp-Gly:454ppm、Glu-Hyp-Gly:24ppm、Ser-Hyp-Gly:239ppm、Gly-Pro:26387ppm、Pro-Ala-Gly:2183ppm、合計:80422ppm。
上記によれば、Pro-Hyp、コラーゲンペプチド混合物Aおよびコラーゲンペプチド混合物Cは、毛乳頭細胞の細胞増殖促進作用を有し、もって育毛剤として、具体的には毛乳頭細胞の細胞増殖促進剤、頭髪における発毛および育毛の促進剤、ならびに脱毛進行予防剤として有効であることが示唆された。
〔試料の準備〕
<アミノ酸、ペプチドおよびコラーゲンペプチド混合物の準備>
毛乳頭細胞に対する細胞増殖促進作用を評価する試料として、市販のアミノ酸であるアラニン(商品名:「L-アラニン」、関東化学株式会社製、カタログ番号:01101-30)、アルギニン(商品名:「L-アルギニン」、富士フィルム和光純薬株式会社製、カタログ番号:015-04613)、グルタミン(商品名:「L-グルタミン」、富士フィルム和光純薬株式会社製、カタログ番号:074-00522)およびプロリン(商品名:「L-プロリン」、富士フィルム和光純薬株式会社製、カタログ番号:161-04602)を準備した。
上述した実施例1における<毛乳頭細胞の準備>の項目で説明したことと同じ方法により、毛乳頭細胞を準備した。
上述した実施例1における〔細胞増殖試験〕の項目で説明したことと同じ要領により、各試料(アミノ酸)が有する毛乳頭細胞の細胞増殖促進作用およびその有意性を評価した。結果を表4に示す。いずれの試料においても、毛乳頭細胞の細胞増殖促進作用を有意に示すとは認められなかった。
表4によれば、アラニン、アルギニン、グルタミおよびプロリンは毛乳頭細胞の細胞増殖促進作用がネガティブであり、Hypなどの特定のアミノ酸に限って毛乳頭細胞の細胞増殖促進作用を有することが示唆された。
Claims (7)
- Hyp、Pro-Hyp、Hyp-Gly、Gly-Pro、Leu-Hyp、Phe-Hyp、Pro-Ala、Pro-Gly、Pro-Pro、Glu-Hyp、Gly-Pro-Hyp、Ala-Hyp-Gly、Glu-Hyp-Gly、Pro-Ala-GlyならびにSer-Hyp-Glyからなる群より選ばれる1以上のアミノ酸またはペプチド、もしくはそれらの塩、あるいはそれらの化学修飾体を含有する、育毛剤。
- 前記アミノ酸および前記ペプチドは、コラーゲン由来である、請求項1に記載の育毛剤。
- 前記育毛剤は、前記アミノ酸または前記ペプチドのいずれかを少なくとも含むコラーゲンペプチド混合物である、請求項1または請求項2に記載の育毛剤。
- 前記コラーゲンペプチド混合物は、その重量平均分子量が100Da以上8000Da以下である、請求項3に記載の育毛剤。
- 前記育毛剤は、毛乳頭細胞の細胞増殖促進剤である、請求項1から請求項4のいずれか1項に記載の育毛剤。
- 前記育毛剤は、頭髪における発毛または育毛の促進剤、あるいは脱毛進行予防剤である、請求項1から請求項5のいずれか1項に記載の育毛剤。
- 請求項1から請求項6のいずれか1項に記載の育毛剤を含む、飲食品。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3137531A CA3137531A1 (en) | 2019-07-25 | 2020-07-13 | Hair growing agent and food or beverage product comprising same |
US17/606,115 US20220305090A1 (en) | 2019-07-25 | 2020-07-13 | Hair growing agent and food or beverage product comprising same |
CN202080047594.5A CN114096270A (zh) | 2019-07-25 | 2020-07-13 | 生发剂和包含其的食品或饮品 |
KR1020227004846A KR20220041113A (ko) | 2019-07-25 | 2020-07-13 | 육모제, 및 이를 포함하는 음식품 |
JP2021533956A JPWO2021015040A1 (ja) | 2019-07-25 | 2020-07-13 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019-137125 | 2019-07-25 | ||
JP2019137125 | 2019-07-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021015040A1 true WO2021015040A1 (ja) | 2021-01-28 |
Family
ID=74193036
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2020/027260 WO2021015040A1 (ja) | 2019-07-25 | 2020-07-13 | 育毛剤、およびこれを含む飲食品 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20220305090A1 (ja) |
JP (1) | JPWO2021015040A1 (ja) |
KR (1) | KR20220041113A (ja) |
CN (1) | CN114096270A (ja) |
CA (1) | CA3137531A1 (ja) |
WO (1) | WO2021015040A1 (ja) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004307370A (ja) * | 2003-04-04 | 2004-11-04 | Kyowa Hakko Kogyo Co Ltd | プロアントシアニジンを含む組成物 |
JP2005281277A (ja) * | 2004-03-31 | 2005-10-13 | Yaizu Suisankagaku Industry Co Ltd | 経口摂取用育毛・養毛組成物及び該組成物を含有する飲食品 |
JP2016088933A (ja) * | 2014-11-01 | 2016-05-23 | 育宏 南 | AGEs産生抑制剤およびその用途 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005029488A (ja) | 2003-07-09 | 2005-02-03 | National Institute Of Advanced Industrial & Technology | 血圧降下剤およびGly−Pro |
JP4033877B2 (ja) * | 2005-09-29 | 2008-01-16 | 株式会社ファンケル | I型コラーゲン産生促進用組成物 |
CL2008001640A1 (es) * | 2007-06-08 | 2008-11-07 | Bergen Teknologioverforing As | Uso de hidroxiprolina para preparar una composicion de alemento destinada a promover el crecimiento de un animal, como peces, aves y mamiferos. |
JP2009120512A (ja) | 2007-11-13 | 2009-06-04 | Nitta Gelatin Inc | 関節軟骨再生促進剤 |
JP2009161509A (ja) | 2008-05-21 | 2009-07-23 | Kanazawa Univ | Xvii型コラーゲンに関する脱毛抑制剤、毛髪の脱色素化抑制剤 |
JP4995155B2 (ja) * | 2008-07-23 | 2012-08-08 | 株式会社ディーエイチシー | 生体コラーゲン合成促進剤並びに生体コラーゲン合成促進用化粧品及び医薬部外品 |
JP4490498B2 (ja) * | 2008-09-30 | 2010-06-23 | 新田ゼラチン株式会社 | 疾病抑制剤 |
TWI507203B (zh) | 2011-01-27 | 2015-11-11 | Nitta Gelatin Kk | The use of a collagen peptide mixture for the manufacture of a therapeutic or prophylactic agent for diabetes mellitus |
CN104271144B (zh) * | 2012-12-13 | 2018-06-26 | 新田明胶株式会社 | 成肌细胞分化促进剂 |
US10213479B2 (en) * | 2014-01-23 | 2019-02-26 | The University Of Kansas | Compounds and methods for increasing hair growth |
JP6860877B2 (ja) * | 2016-09-30 | 2021-04-21 | 株式会社ニッピ | 骨芽細胞の分化促進剤および骨形成促進剤 |
KR101859421B1 (ko) * | 2017-01-31 | 2018-05-21 | 주식회사 케라메딕스 | 탈모방지 또는 발모촉진용 주사용 조성물 |
CN113164769A (zh) * | 2019-02-28 | 2021-07-23 | 新田明胶株式会社 | 脑功能调节剂以及含有其的食品或饮料产品 |
KR20220041119A (ko) * | 2019-07-25 | 2022-03-31 | 니타 젤라틴 가부시키가이샤 | 노화의 진행 억제제, 및 이를 포함하는 음식품 |
-
2020
- 2020-07-13 CN CN202080047594.5A patent/CN114096270A/zh active Pending
- 2020-07-13 US US17/606,115 patent/US20220305090A1/en active Pending
- 2020-07-13 KR KR1020227004846A patent/KR20220041113A/ko active Search and Examination
- 2020-07-13 WO PCT/JP2020/027260 patent/WO2021015040A1/ja active Application Filing
- 2020-07-13 JP JP2021533956A patent/JPWO2021015040A1/ja active Pending
- 2020-07-13 CA CA3137531A patent/CA3137531A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004307370A (ja) * | 2003-04-04 | 2004-11-04 | Kyowa Hakko Kogyo Co Ltd | プロアントシアニジンを含む組成物 |
JP2005281277A (ja) * | 2004-03-31 | 2005-10-13 | Yaizu Suisankagaku Industry Co Ltd | 経口摂取用育毛・養毛組成物及び該組成物を含有する飲食品 |
JP2016088933A (ja) * | 2014-11-01 | 2016-05-23 | 育宏 南 | AGEs産生抑制剤およびその用途 |
Also Published As
Publication number | Publication date |
---|---|
CA3137531A1 (en) | 2021-01-28 |
US20220305090A1 (en) | 2022-09-29 |
KR20220041113A (ko) | 2022-03-31 |
JPWO2021015040A1 (ja) | 2021-01-28 |
CN114096270A (zh) | 2022-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4490498B2 (ja) | 疾病抑制剤 | |
He et al. | Ten new pentapeptides from protein hydrolysate of miiuy croaker (Miichthys miiuy) muscle: Preparation, identification, and antioxidant activity evaluation | |
JP5612131B2 (ja) | 糖尿病の治療または予防剤 | |
Jiang et al. | Purification and characterization of antioxidative peptides from round scad (Decapterus maruadsi) muscle protein hydrolysate | |
Tavares et al. | Novel whey-derived peptides with inhibitory effect against angiotensin-converting enzyme: In vitro effect and stability to gastrointestinal enzymes | |
Je et al. | Purification and characterization of an antioxidant peptide obtained from tuna backbone protein by enzymatic hydrolysis | |
JP5176964B2 (ja) | ジペプチジルペプチダーゼiv阻害剤 | |
JP6100364B2 (ja) | 美白促進剤またはアトピー性皮膚炎改善剤 | |
JP2009120512A (ja) | 関節軟骨再生促進剤 | |
JP5778692B2 (ja) | 疾病抑制剤 | |
WO2021015040A1 (ja) | 育毛剤、およびこれを含む飲食品 | |
US20230016005A1 (en) | Brain function regulating agent, and food or beverage product containing same | |
WO2021015041A1 (ja) | 老化の進行抑制剤、およびこれを含む飲食品 | |
JP6336781B2 (ja) | 新規ペプチド | |
TW202228755A (zh) | 育毛劑及包含其之飲食品 | |
TW202228756A (zh) | 老化之進行抑制劑、及包含其之飲食品 | |
WO2024077483A1 (zh) | 寡肽及其用途及组合物 | |
TW202413388A (zh) | 寡肽及其用途及組成物 | |
JP2006241013A (ja) | ペプチド組成物、繊維芽細胞増殖促進剤およびその製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20843146 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2021533956 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3137531 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20227004846 Country of ref document: KR Kind code of ref document: A |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20843146 Country of ref document: EP Kind code of ref document: A1 |